Literature DB >> 8280613

Gaucher disease mutations in non-Jewish patients.

E Beutler1, T Gelbart.   

Abstract

The DNA from 64 non-Jewish patients with Gaucher disease was examined for 29 different glucocerebrosidase mutations that are known to cause the disease. The most common was mutation 1448C and the second most common 1226G. Twenty of the mutations remained unidentified. These results were compared to those obtained from 122 Jewish patients, in whom the most common mutations were 1226G and 84GG. Among the non-Jewish patients 15.6% of the mutations remained unidentified, while among the Jewish patients only 1.2% remained unidentified, and even screening for the five most common mutations identified all but 2.9% of the Jewish mutations. The greater diversity of mutations among the non-Jewish patients has important implications with respect to DNA-based screening, diagnosis and counselling.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280613     DOI: 10.1111/j.1365-2141.1993.tb03185.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Alglucerase for Gaucher's disease: dose, costs and benefits.

Authors:  E Beutler; A M Garber
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

2.  Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.

Authors:  Zhanqian Yu; Anu R Sawkar; Lisa J Whalen; Chi-Huey Wong; Jeffery W Kelly
Journal:  J Med Chem       Date:  2007-01-11       Impact factor: 7.446

3.  Mutation prevalence among 47 unrelated Japanese patients with Gaucher disease: identification of four novel mutations.

Authors:  H Ida; O M Rennert; H Kawame; K Maekawa; Y Eto
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

4.  ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease.

Authors:  Yun Lei Tan; Joseph C Genereux; Sandra Pankow; Johannes M F G Aerts; John R Yates; Jeffery W Kelly
Journal:  Chem Biol       Date:  2014-08-14

Review 5.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

6.  Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations.

Authors:  H Ida; K Iwasawa; H Kawame; O M Rennert; K Maekawa; Y Eto
Journal:  Hum Genet       Date:  1995-06       Impact factor: 4.132

7.  Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease.

Authors:  Anu R Sawkar; Wei-Chieh Cheng; Ernest Beutler; Chi-Huey Wong; William E Balch; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

8.  Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease.

Authors:  V Koprivica; D L Stone; J K Park; M Callahan; A Frisch; I J Cohen; N Tayebi; E Sidransky
Journal:  Am J Hum Genet       Date:  2000-05-04       Impact factor: 11.025

9.  Glucosylsphingosine is a key biomarker of Gaucher disease.

Authors:  Vagishwari Murugesan; Wei-Lien Chuang; Jun Liu; Andrew Lischuk; Katherine Kacena; Haiqun Lin; Gregory M Pastores; Ruhua Yang; Joan Keutzer; Kate Zhang; Pramod K Mistry
Journal:  Am J Hematol       Date:  2016-08-08       Impact factor: 10.047

10.  Exhaustive screening of the acid beta-glucosidase gene, by fluorescence-assisted mismatch analysis using universal primers: mutation profile and genotype/phenotype correlations in Gaucher disease.

Authors:  D P Germain; J P Puech; C Caillaud; A Kahn; L Poenaru
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.